141 related articles for article (PubMed ID: 7694271)
1. Synthesis and pharmacokinetics of a new liver-specific carrier, glycosylated carboxymethyl-dextran, and its application to drug targeting.
Nishikawa M; Kamijo A; Fujita T; Takakura Y; Sezaki H; Hashida M
Pharm Res; 1993 Sep; 10(9):1253-61. PubMed ID: 7694271
[TBL] [Abstract][Full Text] [Related]
2. Development and pharmacokinetics of galactosylated poly-L-glutamic acid as a biodegradable carrier for liver-specific drug delivery.
Hirabayashi H; Nishikawa M; Takakura Y; Hashida M
Pharm Res; 1996 Jun; 13(6):880-4. PubMed ID: 8792426
[TBL] [Abstract][Full Text] [Related]
3. Biodistribution characteristics of mannosylated, fucosylated, and galactosylated liposomes in mice.
Kawakami S; Wong J; Sato A; Hattori Y; Yamashita F; Hashida M
Biochim Biophys Acta; 2000 Dec; 1524(2-3):258-65. PubMed ID: 11113576
[TBL] [Abstract][Full Text] [Related]
4. Demonstration of the receptor-mediated hepatic uptake of dextran in mice.
Nishikawa M; Yamashita F; Takakura Y; Hashida M; Sezaki H
J Pharm Pharmacol; 1992 May; 44(5):396-401. PubMed ID: 1279155
[TBL] [Abstract][Full Text] [Related]
5. Disposition characteristics of macromolecules in tumor-bearing mice.
Takakura Y; Fujita T; Hashida M; Sezaki H
Pharm Res; 1990 Apr; 7(4):339-46. PubMed ID: 1694582
[TBL] [Abstract][Full Text] [Related]
6. Tissue distribution of 111In-labeled uricase conjugated with charged dextrans and polyethylene glycol.
Fujita T; Yasuda Y; Takakura Y; Hashida M; Sezaki H
J Pharmacobiodyn; 1991 Nov; 14(11):623-9. PubMed ID: 1725532
[TBL] [Abstract][Full Text] [Related]
7. Biodistribution characteristics of galactosylated emulsions and incorporated probucol for hepatocyte-selective targeting of lipophilic drugs in mice.
Ishida E; Managit C; Kawakami S; Nishikawa M; Yamashita F; Hashida M
Pharm Res; 2004 Jun; 21(6):932-9. PubMed ID: 15212156
[TBL] [Abstract][Full Text] [Related]
8. Effect of chemical modification on the pharmacokinetics and biodistribution of carboxymethyl dextran as a drug carrier.
Lee SD; Lim SJ; Kim CK
Drug Deliv; 2002; 9(3):187-93. PubMed ID: 12396736
[TBL] [Abstract][Full Text] [Related]
9. Carrier and dose effects on the pharmacokinetics of T-0128, a camptothecin analogue-carboxymethyl dextran conjugate, in non-tumor- and tumor-bearing rats.
Harada M; Murata J; Sakamura Y; Sakakibara H; Okuno S; Suzuki T
J Control Release; 2001 Mar; 71(1):71-86. PubMed ID: 11245909
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of anti-tumor activity of hybrid peptide in conjugation with carboxymethyl dextran via disulfide linkers.
Gaowa A; Horibe T; Kohno M; Tabata Y; Harada H; Hiraoka M; Kawakami K
Eur J Pharm Biopharm; 2015 May; 92():228-36. PubMed ID: 25801495
[TBL] [Abstract][Full Text] [Related]
11. Targeted delivery and improved therapeutic potential of catalase by chemical modification: combination with superoxide dismutase derivatives.
Yabe Y; Nishikawa M; Tamada A; Takakura Y; Hashida M
J Pharmacol Exp Ther; 1999 May; 289(2):1176-84. PubMed ID: 10215702
[TBL] [Abstract][Full Text] [Related]
12. Disposition characteristics of glycosylated poly(amino acids) as liver cell-specific drug carrier.
Akamatsu K; Imai M; Yamasaki Y; Nishikawa M; Takakura Y; Hashida M
J Drug Target; 1998; 6(3):229-39. PubMed ID: 9888309
[TBL] [Abstract][Full Text] [Related]
13. Design of polymeric prodrugs of prostaglandin E(1) having galactose residue for hepatocyte targeting.
Hashida M; Akamatsu K; Nishikawa M; Yamashita F; Takakura Y
J Control Release; 1999 Nov; 62(1-2):253-62. PubMed ID: 10518658
[TBL] [Abstract][Full Text] [Related]
14. [Magnetic drug delivery system--adriamycin-carboxymethyl dextran magnetic nanoparticles].
Shi K; Li C; He B
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2000 Mar; 17(1):21-4. PubMed ID: 10879185
[TBL] [Abstract][Full Text] [Related]
15. Carboxymethyl dextran-based hypoxia-responsive nanoparticles for doxorubicin delivery.
Son S; Rao NV; Ko H; Shin S; Jeon J; Han HS; Nguyen VQ; Thambi T; Suh YD; Park JH
Int J Biol Macromol; 2018 Apr; 110():399-405. PubMed ID: 29133095
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo study of Gal-OS self-assembled nanoparticles for liver-targeting delivery of doxorubicin.
Guo H; Zhang D; Li T; Li C; Guo Y; Liu G; Hao L; Shen J; Qi L; Liu X; Luan J; Zhang Q
J Pharm Sci; 2014 Mar; 103(3):987-93. PubMed ID: 24549734
[TBL] [Abstract][Full Text] [Related]
17. Assessment of targeting potential of galactosylated and mannosylated sterically stabilized liposomes to different cell types of mouse liver.
Nag A; Ghosh PC
J Drug Target; 1999; 6(6):427-38. PubMed ID: 10937288
[TBL] [Abstract][Full Text] [Related]
18. Development and in vivo characterization of a novel peptide drug delivery system providing extended plasma half life.
Shahnaz G; Iqbal J; Rahmat D; Perera G; Laffleur F; Rossi D; Bernkop-Schnürch A
J Control Release; 2012 Feb; 157(3):375-82. PubMed ID: 21986100
[TBL] [Abstract][Full Text] [Related]
19. Carrier effects on antitumor activity and neurotoxicity of AZ10992, a paclitaxel-carboxymethyl dextran conjugate, in a mouse model.
Sugahara S; Kajiki M; Kuriyama H; Kobayashi TR
Biol Pharm Bull; 2008 Feb; 31(2):223-30. PubMed ID: 18239277
[TBL] [Abstract][Full Text] [Related]
20. Novel galactosylated liposomes for hepatocyte-selective targeting of lipophilic drugs.
Kawakami S; Munakata C; Fumoto S; Yamashita F; Hashida M
J Pharm Sci; 2001 Feb; 90(2):105-13. PubMed ID: 11169527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
